Business Description
Acurx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00510M1045
Share Class Description:
FRA:3ZO0: Ordinary SharesTotal Employee Number:
4Description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.74 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37.7 | |||||
3-Year EPS without NRI Growth Rate | 38.1 | |||||
3-Year FCF Growth Rate | 31.3 | |||||
3-Year Book Growth Rate | -43.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.88 | |||||
Quick Ratio | 3.88 | |||||
Cash Ratio | 3.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -59.3 | |||||
Shareholder Yield % | -155.38 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -135.8 | |||||
ROA % | -92.72 | |||||
ROIC % | -19971.35 | |||||
3-Year ROIIC % | -793.85 | |||||
ROCE % | -138.75 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.74 | |||||
Price-to-Tangible-Book | 0.74 | |||||
EV-to-EBIT | 0.6 | |||||
EV-to-Forward-EBIT | -0.4 | |||||
EV-to-EBITDA | 0.6 | |||||
EV-to-Forward-EBITDA | -0.4 | |||||
EV-to-FCF | 0.74 | |||||
| Price-to-Net-Current-Asset-Value | 0.74 | |||||
| Price-to-Net-Cash | 0.77 | |||||
Earnings Yield (Greenblatt) % | 166.67 | |||||
FCF Yield % | -102.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acurx Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.309 | ||
| Beta | -6.2324 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 11.71 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 5.09 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 5.09 - 5.09 | ||
| Shares Outstanding (Mil) | 4.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acurx Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acurx Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:00 | In 63 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 62 days | ||
| General meeting for 2026 | 2026-10-16 10:00 | In 36 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:00 | 5.09 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 5.09 (+0.00%) | ||
| Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare | 2026-05-20 | 5.09 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:00 | 5.09 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 5.09 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-13 08:00 | 5.09 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-13 | 5.09 (+0.00%) |
Show
Entries
Acurx Pharmaceuticals Inc Frequently Asked Questions
What is Acurx Pharmaceuticals Inc(FRA:3ZO0)'s stock price today?
The current price of FRA:3ZO0 is €5.09. The 52 week high of FRA:3ZO0 is €5.09 and 52 week low is €5.09.
When is next earnings date of Acurx Pharmaceuticals Inc(FRA:3ZO0)?
The next earnings date of Acurx Pharmaceuticals Inc(FRA:3ZO0) is 2026-11-12 Est..
Does Acurx Pharmaceuticals Inc(FRA:3ZO0) pay dividends? If so, how much?
Acurx Pharmaceuticals Inc(FRA:3ZO0) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers